These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17409952)

  • 1. Angiogenesis inhibitors for lung cancer: clinical developments and future directions.
    Blumenschein G; Heymach JV
    J Thorac Oncol; 2006 Sep; 1(7):744-8. PubMed ID: 17409952
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Subramanian J; Morgensztern D; Govindan R
    Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?
    Carbognin L; Pilotto S; Peretti U; Tortora G; Bria E
    Expert Opin Investig Drugs; 2016 Jun; 25(6):635-8. PubMed ID: 27054716
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapies in lung cancer.
    Besse B; Ropert S; Soria JC
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
    Byers LA; Heymach JV
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S79-85. PubMed ID: 17382029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy and new anticancer drugs in advanced disease.
    Silva S; Danson S
    Thorac Surg Clin; 2013 Aug; 23(3):411-9. PubMed ID: 23931023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
    Villaruz LC; Socinski MA
    Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
    Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
    Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label uses of bevacizumab: breast and lung cancer indications.
    Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
    [No Abstract]   [Full Text] [Related]  

  • 14. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
    Wang S; Yang Z; Wang Z
    Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
    Garfield D
    J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
    Reckamp KL
    Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.